Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Jump to content

Dopaminergic

From Wikipedia, the free encyclopedia
The chemical structure of the neurotransmitter dopamine
Look up dopaminergic in Wiktionary, the free dictionary.

Dopaminergic means "related to dopamine" (literally, "working on dopamine"), a common neurotransmitter.[1] Dopaminergic substances or actions increase dopamine-related activity in the brain.

Dopaminergic brain pathways facilitate dopamine-related activity. For example, certain proteins such as the dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT2), and dopamine receptors can be classified as dopaminergic, and neurons that synthesize or contain dopamine and synapses with dopamine receptors in them may also be labeled as dopaminergic. Enzymes that regulate the biosynthesis or metabolism of dopamine such as aromatic L-amino acid decarboxylase or DOPA decarboxylase, monoamine oxidase (MAO), and catechol O-methyl transferase (COMT) may be referred to as dopaminergic as well.

Also, any endogenous or exogenous chemical substance that acts to affect dopamine receptors or dopamine release through indirect actions (for example, on neurons that synapse onto neurons that release dopamine or express dopamine receptors) can also be said to have dopaminergic effects, two prominent examples being opioids, which enhance dopamine release indirectly in the reward pathways, and some substituted amphetamines, which enhance dopamine release directly by binding to and inhibiting VMAT2.

Dopaminergic agents

[edit]
See also: List of dopaminergic drugs

Dopamine precursors

[edit]
Main article: Monoamine precursor

Dopamine precursors including L-phenylalanine and L-tyrosine are used as dietary supplements. L-DOPA (Levodopa), another precursor, is used in the treatment of Parkinson's disease. Prodrugs of levodopa, including melevodopa, etilevodopa, foslevodopa, and XP-21279 also exist. They are inactive themselves but are converted into dopamine and hence act as non-selective dopamine receptor agonists.

Dopamine receptor ligands

[edit]

Dopamine receptor agonists

[edit]
Main article: Dopamine receptor agonist

Dopamine receptor agonists can be divided into non-selective dopamine receptor agonists, D1-like receptor agonists, and D2-like receptor agonists.

Non-selective dopamine receptor agonists include dopamine, deoxyepinephrine (epinine), dinoxyline, and dopexamine. They are mostly peripherally selective drugs, are often also adrenergic receptor agonists, and are used to treat certain cardiovascular conditions.

D2-like receptor agonists include the ergolines bromocriptine, cabergoline, dihydroergocryptine, ergoloid, lisuride, metergoline, pergolide, quinagolide, and terguride; the morphine analogue apomorphine; and the structurally distinct agents piribedil, pramipexole, ropinirole, rotigotine, and talipexole. Some of these agents also have weak affinity for the D1-like receptors. They are used to treat Parkinson's disease, restless legs syndrome, hyperprolactinemia, prolactinomas, acromegaly, erectile dysfunction, and for lactation suppression. They are also being studied in the treatment of depression and are sometimes used in the treatment of disorders of diminished motivation like apathy, abulia, and akinetic mutism.

D1-like receptor agonists include 6-Br-APB, A-68930, A-77636, A-86929, adrogolide, dihydrexidine, dinapsoline, doxanthrine, fenoldopam, razpipadon, SKF-81,297, SKF-82,958, SKF-89,145, tavapadon, and trepipam. They have been researched for and are under development for the treatment of Parkinson's disease and dementia-related apathy. Peripherally selective D1-like receptor agonists like fenoldopam are used to treat hypertensive crisis.

Dopamine receptor positive allosteric modulators

[edit]

Positive allosteric modulators of the dopamine D1 receptor like mevidalen and glovadalen are under development for the treatment of Lewy body disease and Parkinson's disease.

Dopamine receptor antagonists

[edit]
Main article: Dopamine receptor antagonist

Dopamine receptor antagonists including typical antipsychotics such as chlorpromazine (Thorazine), fluphenazine, haloperidol (Haldol), loxapine, molindone, perphenazine, pimozide, thioridazine, thiothixene, and trifluoperazine, the atypical antipsychotics such as amisulpride, clozapine, olanzapine, quetiapine (Seroquel), risperidone (Risperdal), sulpiride, and ziprasidone, and antiemetics like domperidone, metoclopramide, and prochlorperazine, among others, which are used in the treatment of schizophrenia and bipolar disorder as antipsychotics, and nausea and vomiting.

Dopamine receptor antagonists can be divided into D1-like receptor antagonists and D2-like receptor antagonists. Ecopipam is an example of a D1-like receptor antagonist.

At low doses, dopamine D2 and D3 receptor antagonists can preferentially block presynaptic dopamine D2 and D3 autoreceptors and thereby increase dopamine levels and enhance dopaminergic neurotransmission.[2][3][4] Examples of dopamine D2 and D3 receptor antagonists which have been used in this way include amisulpride,[3][5][6] sulpiride,[7][8][9][10] and ENX-104.[11][12]

Dopamine receptor negative allosteric modulators

[edit]

Negative allosteric modulators of the dopamine receptors, such as SB269652, have been identified and are being researched.[13][14][15][16]

[edit]

Dopamine reuptake inhibitors

[edit]
Main article: Dopamine reuptake inhibitor

Dopamine reuptake inhibitors (DRIs) or dopamine transporter (DAT) inhibitors such as methylphenidate (Ritalin), amineptine, nomifensine, cocaine, bupropion, modafinil, armodafinil, phenylpiracetam, mesocarb, and vanoxerine, among others. They are used in the treatment of attention-deficit hyperactivity disorder (ADHD) as psychostimulants, narcolepsy as wakefulness-promoting agents, obesity and binge eating disorder as appetite suppressants, depression as antidepressants, and fatigue as pro-motivational agents. They are also used as illicit street and recreational drugs due to their euphoriant and psychostimulant effects.

Dopamine releasing agents

[edit]
Main article: Dopamine releasing agent

Dopamine releasing agents (DRAs) such as phenethylamine, amphetamine, lisdexamfetamine (Vyvanse), methamphetamine, methylenedioxymethamphetamine (MDMA), phenmetrazine, pemoline, 4-methylaminorex (4-MAR), phentermine, and benzylpiperazine, among many others, which, like DRIs, are used in the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy as psychostimulants, obesity as anorectics, depression and anxiety as antidepressants and anxiolytics respectively, drug addiction as anticraving agents, and sexual dysfunction as aphrodisiacs. Many of these compounds are also illicit street or recreational drugs.

Dopaminergic activity enhancers

[edit]
Main article: Monoaminergic activity enhancer

Dopaminergic activity enhancers such as the prescription drug selegiline (deprenyl) and the research chemicals BPAP and PPAP enhance the action potential-mediated release of dopamine.[17] This is in contrast to dopamine releasing agents like amphetamine, which induce the uncontrolled release of dopamine regardless of electrical stimulation.[17] The effects of the activity enhancers may be mediated by intracellular TAAR1 agonism coupled with uptake into monoaminergic neurons by monoamine transporters.[18][19] Dopaminergic activity enhancers are of interest in the potential treatment of a number of medical disorders, such as depression and Parkinson's disease. To date, only phenylethylamine, tryptamine, and tyramine have been identified as endogenous activity enhancers.[17]

Dopamine depleting agents

[edit]
Main article: Monoamine depleting agent

Vesicular monoamine transporter 2 (VMAT2) inhibitors such as reserpine, tetrabenazine, valbenazine, and deutetrabenazine act as dopamine depleting agents and are used as sympatholytics or antihypertensives, to treat tardive dyskinesia, and in the past as antipsychotics. They have been associated with side effects including depression, apathy, fatigue, amotivation, and suicidality.

Dopamine metabolism modulators

[edit]

Monoamine oxidase inhibitors

[edit]
Main article: Monoamine oxidase inhibitor

Monoamine oxidase (MAO) inhibitors (MAOIs) including non-selective agents such as phenelzine, tranylcypromine, isocarboxazid, and pargyline, MAOA selective agents like moclobemide and clorgyline, and MAOB selective agents such as selegiline and rasagiline, as well as the harmala alkaloids like harmine, harmaline, tetrahydroharmine, harmalol, harman, and norharman, which are found to varying degrees in Nicotiana tabacum (tobacco), Banisteriopsis caapi (ayahuasca, yage), Peganum harmala (Harmal, Syrian Rue), Passiflora incarnata (Passion Flower), and Tribulus terrestris, among others, which are used in the treatment of depression and anxiety as antidepressants and anxiolytics, respectively, in the treatment of Parkinson's disease and dementia, and for the recreational purpose of boosting the effects of certain drugs like phenethylamine (PEA) and psychedelics like dimethyltryptamine (DMT) via inhibiting their metabolism.

Catechol O-methyltransferase inhibitors

[edit]
Main article: Catechol-O-methyltransferase inhibitor

Catechol O-methyl transferase (COMT) inhibitors such as entacapone, opicapone, and tolcapone, which are used in the treatment of Parkinson's disease. Entacapone and opicapone are peripherally selective, but tolcapone significantly crosses the blood–brain barrier. Tolcapone is under study for potential treatment of certain psychiatric disorders such as obsessive–compulsive disorder and schizophrenia.[20][21][22]

Aromatic L-amino acid decarboxylase inhibitors

[edit]
Main article: Aromatic L-amino acid decarboxylase inhibitor

Aromatic L-amino acid decarboxylase (AAAD) or DOPA decarboxylase inhibitors including benserazide, carbidopa, and methyldopa, which are used in the treatment of Parkinson's disease in augmentation of L-DOPA to block the peripheral conversion of dopamine, thereby inhibiting undesirable side-effects, and as sympatholytic or antihypertensive agents.

Dopamine β-hydroxylase inhibitors

[edit]

Dopamine β-hydroxylase inhibitors like disulfiram (Antabuse), which can be used in the treatment of addiction to cocaine and similar dopaminergic drugs as a deterrent drug. The excess dopamine resulting from inhibition of the dopamine β-hydroxylase enzyme increases unpleasant symptoms such as anxiety, higher blood pressure, and restlessness. Disulfiram is not an anticraving agent, because it does not decrease craving for drugs. Instead, positive punishment from its unpleasant effects deters drug consumption.[23] Other dopamine β-hydroxylase inhibitors include the centrally active nepicastat and the peripherally selective etamicastat and zamicastat.

Other enzyme inhibitors

[edit]

Phenylalanine hydroxylase inhibitors like 3,4-dihydroxystyrene), which is currently only a research chemical with no suitable therapeutic indications, likely because such drugs would induce the potentially highly dangerous hyperphenylalaninemia or phenylketonuria.

Tyrosine hydroxylase inhibitors like metirosine, which is used in the treatment of pheochromocytoma as a sympatholytic or antihypertensive agent.

Dopaminergic neurotoxins

[edit]

Dopaminergic neurotoxins like 6-hydroxydopamine (6-OHDA) and MPTP are used in scientific research to lesion the dopamine system and study the biological role of dopamine.

Miscellaneous agents

[edit]

Adamantane derivatives

[edit]

Amantadine has dopaminergic effects through uncertain mechanisms of action.[24][25] It is structurally related to other adamantanes like bromantane and rimantadine, which also have dopaminergic actions.[26] Bromantane can upregulate tyrosine hydroxylase (TH) and thereby increase dopamine production and this might be involved in its dopaminergic effects.[27][28] Amantadine can upregulate TH similarly, but as with bromantane, it is unclear whether this is involved in or responsible for its dopaminergic actions.[24] Amantadine is used in the treatment of Parkinson's disease, levodopa-induced dyskinesia, and fatigue in multiple sclerosis. It has also been used in the treatment of disorders of consciousness, disorders of diminished motivation, and brain injuries. The drug is being studied in the treatment of depression and attention deficit hyperactivity disorder (ADHD) as well.

Diphenylpiperidines

[edit]

4,4-Diphenylpiperidines including budipine and prodipine are effective in the treatment of Parkinson's disease.[29][30][31] Their mechanism of action is unknown but they act as indirect dopaminergic agents.[30][29][31] They have distinct effects from other antiparkinsonian agents and dopaminergic drugs.[30][29][31]

Other miscellaneous agents

[edit]

Aspirin upregulates tyrosine hydroxylase and increases dopamine production.[32]

Others such as hyperforin and adhyperforin (both found in Hypericum perforatum St. John's Wort), L-theanine (found in Camellia sinensis, the tea plant), and S-adenosyl-L-methionine (SAMe).

See also

[edit]

References

[edit]
  1. ^ Melinosky C (27 November 2022). "Parkinson's Disease: Glossary of Terms". WebMD.
  2. ^ Möller HJ (June 2005). "Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?". Eur Arch Psychiatry Clin Neurosci. 255 (3): 190–201. doi:10.1007/s00406-005-0587-5. PMID 15995903.
  3. ^ a b Curran MP, Perry CM (2002). "Spotlight on amisulpride in schizophrenia". CNS Drugs. 16 (3): 207–211. doi:10.2165/00023210-200216030-00007. PMID 11888341.
  4. ^ Pani L, Gessa GL (2002). "The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia". Mol Psychiatry. 7 (3): 247–253. doi:10.1038/sj.mp.4001040. PMID 11920152.
  5. ^ McKeage K, Plosker GL (2004). "Amisulpride: a review of its use in the management of schizophrenia". CNS Drugs. 18 (13): 933–956. doi:10.2165/00023210-200418130-00007. PMID 15521794.
  6. ^ Wu J, Kwan AT, Rhee TG, Ho R, d'Andrea G, Martinotti G, Teopiz KM, Ceban F, McIntyre RS (2023). "A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia". Expert Rev Clin Pharmacol. 16 (11): 1085–1092. doi:10.1080/17512433.2023.2274538. PMID 37864424.
  7. ^ Serra G, Forgione A, D'Aquila PS, Collu M, Fratta W, Gessa GL (1990). "Possible mechanism of antidepressant effect of L-sulpiride". Clin Neuropharmacol. 13 Suppl 1: S76–S83. doi:10.1097/00002826-199001001-00009. PMID 2199037.
  8. ^ Wagstaff, Antona J.; Fitton, Andrew; Benfield, Paul (1994). "Sulpiride". CNS Drugs. 2 (4). Springer Science and Business Media LLC: 313–333. doi:10.2165/00023210-199402040-00007. ISSN 1172-7047.
  9. ^ Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi G (May 1996). "A risk-benefit assessment of sulpiride in the treatment of schizophrenia". Drug Saf. 14 (5): 288–298. doi:10.2165/00002018-199614050-00003. PMID 8800626.
  10. ^ Ohmann HA, Kuper N, Wacker J (2020). "A low dosage of the dopamine D2-receptor antagonist sulpiride affects effort allocation for reward regardless of trait extraversion". Personal Neurosci. 3: e7. doi:10.1017/pen.2020.7. PMC 7327436. PMID 32656492.
  11. ^ Vadodaria K, Kangas BD, Garvey DS, Brubaker W, Pizzagalli DA, Sudarsan V, Vanover KE, Serrats J (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P351. Anti-Anhedonic Profile of ENX-104, a Novel and Highly Potent Dopamine D2/3 Receptor Antagonist". Neuropsychopharmacology. 47 (Suppl 1): 220–370 (265–266). doi:10.1038/s41386-022-01485-0. PMC 9714399. PMID 36456694.
  12. ^ Vadodaria K, Serrats J, Brubaker W, Sudarsan V, Vanover K (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 - P500: P356. ENX-104, a Novel and Potent D2/3 Receptor Antagonist, Increased Extracellular Levels of Dopamine and Serotonin in the Nucleus Accumbens and Prefrontal Cortex of Freely-Moving Rats". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (271–272). doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
  13. ^ Rossi M, Fasciani I, Marampon F, Maggio R, Scarselli M (June 2017). "The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs". Mol Pharmacol. 91 (6): 586–594. doi:10.1124/mol.116.107607. PMC 5438131. PMID 28265019.
  14. ^ Girmaw F (March 2024). "Review on allosteric modulators of dopamine receptors so far". Health Sci Rep. 7 (3): e1984. doi:10.1002/hsr2.1984. PMC 10948587. PMID 38505681.
  15. ^ Soriano A, Vendrell M, Gonzalez S, Mallol J, Albericio F, Royo M, Lluís C, Canela EI, Franco R, Cortés A, Casadó V (March 2010). "A hybrid indoloquinolizidine peptide as allosteric modulator of dopamine D1 receptors". J Pharmacol Exp Ther. 332 (3): 876–885. doi:10.1124/jpet.109.158824. PMID 20026675.
  16. ^ Shonberg J, Draper-Joyce C, Mistry SN, Christopoulos A, Scammells PJ, Lane JR, Capuano B (July 2015). "Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor". J Med Chem. 58 (13): 5287–5307. doi:10.1021/acs.jmedchem.5b00581. PMID 26052807.
  17. ^ a b c Shimazu S, Miklya I (May 2004). "Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28 (3): 421–427. doi:10.1016/j.pnpbp.2003.11.016. PMID 15093948. S2CID 37564231.
  18. ^ Harsing LG, Knoll J, Miklya I (August 2022). "Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum". Int J Mol Sci. 23 (15): 8543. doi:10.3390/ijms23158543. PMC 9369307. PMID 35955676.
  19. ^ Harsing LG, Timar J, Miklya I (August 2023). "Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline". Int J Mol Sci. 24 (17): 13334. doi:10.3390/ijms241713334. PMC 10487936. PMID 37686140.
  20. ^ Kings E, Ioannidis K, Grant JE, Chamberlain SR (June 2024). "A systematic review of the cognitive effects of the COMT inhibitor, tolcapone, in adult humans". CNS Spectr. 29 (3): 166–175. doi:10.1017/S1092852924000130. PMID 38487834.
  21. ^ Grant JE, Hook R, Valle S, Chesivoir E, Chamberlain SR (September 2021). "Tolcapone in obsessive-compulsive disorder: a randomized double-blind placebo-controlled crossover trial". Int Clin Psychopharmacol. 36 (5): 225–229. doi:10.1097/YIC.0000000000000368. PMC 7611531. PMID 34310432.
  22. ^ Apud JA, Weinberger DR (2007). "Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors". CNS Drugs. 21 (7): 535–557. doi:10.2165/00023210-200721070-00002. PMID 17579498.
  23. ^ Krampe H, Stawicki S, Wagner T, Bartels C, Aust C, Rüther E, Poser W, Ehrenreich H (January 2006). "Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome". Alcoholism: Clinical and Experimental Research. 30 (1): 86–95. doi:10.1111/j.1530-0277.2006.00013.x. PMID 16433735.
  24. ^ a b Huber TJ, Dietrich DE, Emrich HM (March 1999). "Possible use of amantadine in depression". Pharmacopsychiatry. 32 (2): 47–55. doi:10.1055/s-2007-979191. PMID 10333162.
  25. ^ Danysz W, Dekundy A, Scheschonka A, Riederer P (February 2021). "Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials". J Neural Transm (Vienna). 128 (2): 127–169. doi:10.1007/s00702-021-02306-2. PMC 7901515. PMID 33624170.
  26. ^ Ragshaniya A, Kumar V, Tittal RK, Lal K (March 2024). "Nascent pharmacological advancement in adamantane derivatives". Arch Pharm (Weinheim). 357 (3): e2300595. doi:10.1002/ardp.202300595. PMID 38128028.
  27. ^ Mikhaylova M, Vakhitova JV, Yamidanov RS, Salimgareeva MK, Seredenin SB, Behnisch T (October 2007). "The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats". Neuropharmacology. 53 (5): 601–608. doi:10.1016/j.neuropharm.2007.07.001. PMID 17854844. S2CID 43661752.
  28. ^ Voznesenskaia TG, Fokina NM, Iakhno NN (2010). "[Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten]". Zhurnal Nevrologii I Psikhiatrii imeni S.S. Korsakova. 110 (5 Pt 1): 17–26. PMID 21322821.
  29. ^ a b c Przuntek, H.; Stasch, J.-P. (1985). "Biochemical and Pharmacologic Aspects of the Mechanism of Action of Budipine". Clinical Experiences with Budipine in Parkinson Therapy. Berlin, Heidelberg: Springer Berlin Heidelberg. p. 107–112. doi:10.1007/978-3-642-95455-9_15. ISBN 978-3-540-13764-1.
  30. ^ a b c Przuntek H (April 2000). "Non-dopaminergic therapy in Parkinson's disease". J Neurol. 247 Suppl 2: II19–24. doi:10.1007/pl00007756. PMID 10991661.
  31. ^ a b c Eltze M (1999). "Multiple mechanisms of action: the pharmacological profile of budipine". J Neural Transm Suppl. 56: 83–105. doi:10.1007/978-3-7091-6360-3_4. PMID 10370904.
  32. ^ Rangasamy SB, Dasarathi S, Pahan P, Jana M, Pahan K (June 2019). "Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease". Journal of Neuroimmune Pharmacology. 14 (2): 173–187. doi:10.1007/s11481-018-9808-3. PMC 6401361. PMID 30187283.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Dopaminergic&oldid=1258686799"